Furthermore, upregulated of ROS related signatures are observed in residual tumors from TKI‐treated patients with EGFR+ NSCLC, HER2+ breast cancer, and BRAF+ melanoma [27], suggesting that the findings of our study with ALK+ NSCLC cells may also possibly be observed in patients with ALK+ NSCLC. This evidence concerns the gene EGFR and breast cancer.